These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 999987)

  • 21. Naltrexone: report of lack of hepatotoxicity in acute viral hepatitis, with a review of the literature.
    Brewer C; Wong VS
    Addict Biol; 2004 Mar; 9(1):81-7. PubMed ID: 15203443
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Use of naltrexone in the treatment of young drug addicts].
    Waal H; Aamodt Ø; Olsen H
    Tidsskr Nor Laegeforen; 2003 Jun; 123(12):1662-4. PubMed ID: 12821983
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EEG and other effects of naltrexone and heroin in man.
    Volavka J; James B; Reker D; Mallya A; Cho D; Pevnick J
    Pharmakopsychiatr Neuropsychopharmakol; 1979 Jan; 12(1):79-85. PubMed ID: 570272
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of heroin dependence with naltrexone.
    Martin WR
    Curr Psychiatr Ther; 1975; 15():157-61. PubMed ID: 1181122
    [No Abstract]   [Full Text] [Related]  

  • 25. A comparison of mental health hospital admissions in a cohort of heroin users prior to and after rapid opiate detoxification and oral naltrexone maintenance.
    Arnold-Reed DE; O'Neil P; Holman CD; Bulsara MK; Rodiguez C; Gawthorne G; Tait RJ; Hulse GK
    Am J Drug Alcohol Abuse; 2007; 33(5):655-64. PubMed ID: 17891658
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antagonist-precipitated heroin withdrawal under anaesthetic prior to maintenance naltrexone treatment: determinants of withdrawal severity.
    Ali R; Thomas P; White J; McGregor C; Danz C; Gowing L; Stegink A; Athanasos P
    Drug Alcohol Rev; 2003 Dec; 22(4):425-31. PubMed ID: 14660132
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nontolerance to the opioid antagonism of naltrexone.
    Kleber HD; Kosten TR; Gaspari J; Topazian M
    Biol Psychiatry; 1985 Jan; 20(1):66-72. PubMed ID: 2981129
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A new approach to preventing relapse in opiate addicts: a psychometric evaluation.
    Grüsser SM; Thalemann CN; Platz W; Gölz J; Partecke G
    Biol Psychol; 2006 Mar; 71(3):231-5. PubMed ID: 16046046
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patient response to naltrexone: issues of acceptance, treatment effects, and frequency of administration.
    Curran S; Savage C
    NIDA Res Monogr; 1976 Sep; (9):67-9. PubMed ID: 794722
    [No Abstract]   [Full Text] [Related]  

  • 30. [Detoxification treatment with naltrexone in opiate dependence].
    Ochoa Mangado E; López-Ibor Aliño JJ; Pérez de los Cobos Peris JC; Cebollada Gracia A
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1992; 20(5):215-29. PubMed ID: 1462806
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Role of LAAM, methadone and naltrexone in the care of opiate dependence. Experience in Portugal].
    Patricio LD; Miguel N
    Ann Med Interne (Paris); 1994 Nov; 145 Suppl 3():28-30. PubMed ID: 7880010
    [No Abstract]   [Full Text] [Related]  

  • 32. Craving in heroin addicts maintained on the opiate antagonist naltrexone.
    Sideroff SI; Charuvastra VC; Jarvik ME
    Am J Drug Alcohol Abuse; 1978; 5(4):415-23. PubMed ID: 755381
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 24-Hour opiate detoxification and antagonist induction at home--the 'Asturian method': a report on 1368 procedures.
    Carreño JE; Bobes J; Brewer C; Alvarez CE; San Narciso GI; Bascarán MT; Sánchez del Río J
    Addict Biol; 2002 Apr; 7(2):243-50. PubMed ID: 12006220
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Unreinforced self-injections: effects on rituals and outcome in heroin addicts.
    O'Brien CP; Greenstein R; Ternes J; McLellan AT; Grabowski J
    NIDA Res Monogr; 1979; 27():275-81. PubMed ID: 95035
    [No Abstract]   [Full Text] [Related]  

  • 35. Clinical experience with naltrexone.
    O'Brien CP; Greenstein RA; Mintz J; Woody GE
    Am J Drug Alcohol Abuse; 1975; 2(3-4):365-77. PubMed ID: 1227298
    [No Abstract]   [Full Text] [Related]  

  • 36. Use of naltrexone to extinguish opioid-conditioned responses.
    O'Brien CP; Childress AR; McLellan AT; Ternes J; Ehrman RN
    J Clin Psychiatry; 1984 Sep; 45(9 Pt 2):53-6. PubMed ID: 6381473
    [TBL] [Abstract][Full Text] [Related]  

  • 37. NIDA's naltrexone research program.
    Julius D
    NIDA Res Monogr; 1976 Sep; (9):5-11. PubMed ID: 187943
    [No Abstract]   [Full Text] [Related]  

  • 38. Update of naltrexone treatment.
    O'Brien CP; Greenstein R; Woody GE
    NIDA Res Monogr; 1978; (19):315-20. PubMed ID: 218107
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Naltrexone in methadone maintenance patients electing to become "drug free".
    Haas N; Ling W; Holmes E; Blakis M; Litaker M
    NIDA Res Monogr; 1976 Sep; (9):70-3. PubMed ID: 794723
    [No Abstract]   [Full Text] [Related]  

  • 40. Long-acting depot formulations of naltrexone for heroin dependence: a review.
    Krupitsky EM; Blokhina EA
    Curr Opin Psychiatry; 2010 May; 23(3):210-4. PubMed ID: 20224403
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.